Metabolism of atenolol in man

Xenobiotica; the Fate of Foreign Compounds in Biological Systems
P R ReevesM J Winrow

Abstract

1. The disposition and metabolism of 1-(4-carbamoyl[14C]methylphenoxy)-3-isopropylaminopan-2-ol (atenolol, Tenormin) has been studied in man following oral and intravenous doses. 2. Approx. 50% of an oral dose was eliminated in urine; the major radiolabelled component was atenolol (approx. 90%). Faecal extracts also contained largely unchanged atenolol, with small amounts of more polar metabolites. Biliary excretion of atenolol and its metabolites is not a major route of elimination in man. Metabolism of the compound is not extensive and route-dependent modes of metabolism do not appear to complicate the position. 3. Atenolol appeared to be the only major radiolabelled component in blood. 4. Oral doses of atenolol are incompletely absorbed (range 46-62%), even when formulated as a solution. 5. 1-[4-(C-Carbamoylhydroxymethyl)phenoxy]-3-isopropylaminopropan-2-ol was a minor urinary metabolite, which has only one tenth the activity of the parent compound as a beta-adrenergic blocking agent in the rat. 6. Pharmacological activity in man appears to be due to atenolol alone.

References

Nov 1, 1976·Clinical Pharmacology and Therapeutics·H C BrownR G Shanks
May 1, 1978·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·P R ReevesM J Winrow
May 17, 1975·British Medical Journal·L HanssonA Westerlund
Jun 1, 1975·The Journal of Pharmacy and Pharmacology·B Scales, P B Copsey
Apr 24, 1976·British Medical Journal·A P Douglas-Jones, J M Cruickshank
Apr 1, 1975·British Journal of Clinical Pharmacology·G E MarlinP Turner
Dec 1, 1974·British Journal of Clinical Pharmacology·C M Kaye

Citations

Jan 1, 1981·European Journal of Clinical Pharmacology·J D HarryN P Barker
Jan 1, 1981·European Journal of Clinical Pharmacology·W KirchM Schäfer
May 1, 1980·European Journal of Clinical Pharmacology·E RivaJ McAinsh
May 17, 1978·European Journal of Clinical Pharmacology·J D FitzgeraldJ McAinsh
Jan 1, 1982·European Journal of Drug Metabolism and Pharmacokinetics·W Kirch, K G Görg
Oct 1, 1983·European Journal of Drug Metabolism and Pharmacokinetics·W MeuldermansJ Heykants
Jan 1, 1979·European Journal of Drug Metabolism and Pharmacokinetics·K J HoffmannK O Borg
Jan 1, 1987·European Journal of Drug Metabolism and Pharmacokinetics·A CelardoM Bonati
May 1, 1994·Pharmaceutica acta Helvetiae·J S DemouF M Plakogiannis
Jan 1, 1980·Pharmacology & Therapeutics·B N Prichard, C W Owens
Apr 6, 2002·Reproductive Toxicology·Sonia A Tabacova, Carole A Kimmel
Jun 17, 1982·The New England Journal of Medicine·W H Frishman
Sep 17, 2008·Pharmacogenetics and Genomics·Daniel KurnikC Michael Stein
Apr 1, 1986·Journal of Pharmacological Methods·G L TrainaM Bonati
Jul 1, 2008·Expert Review of Clinical Pharmacology·Amit S KalgutkarJonathan Bauman
Jul 6, 2014·Expert Opinion on Drug Metabolism & Toxicology·Slobodan M Jankovic
Jan 1, 1984·Drug Metabolism Reviews·E J Calabrese
Jul 1, 1992·The American Journal of Medicine·D L Geffner, J M Hershman
Sep 1, 1984·British Journal of Clinical Pharmacology·A K SalahudeenD N Bateman
Apr 1, 1980·British Journal of Clinical Pharmacology·B FlouvatA Baglin
Feb 1, 1982·British Journal of Clinical Pharmacology·P C RubinJ L Reid
Jan 1, 1983·Biopharmaceutics & Drug Disposition·W KirchE Mutschler
Jan 1, 1981·Biopharmaceutics & Drug Disposition·C G RegårdhB A Persson
Apr 1, 1983·Journal of Clinical Pharmacology·W KirchW Braun
Jul 1, 1982·British Journal of Clinical Pharmacology·J J HoutzagersC G Regårdh
May 1, 1986·Biopharmaceutics & Drug Disposition·J McAinshJ Young
Jan 1, 1984·British Journal of Clinical Pharmacology·M E EllisT J Fitzsimons
Jan 1, 1984·British Journal of Clinical Pharmacology·B K Park
Aug 19, 2014·The Science of the Total Environment·Christoph SteinbachHana Kocour Kroupova
Jan 30, 2008·The Analyst·Yohannes H RezenomKermit K Murray
Aug 10, 2016·Molecular Pharmaceutics·David DahlgrenHans Lennernäs
Mar 1, 1989·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M ColomboN Dioguardi
Dec 29, 2007·The Journal of Pharmacology and Experimental Therapeutics·Tamara J van SteegElizabeth C M de Lange
Sep 1, 2006·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Toshiro NiwaAkira Takagi
Apr 29, 2019·Clinical Pharmacokinetics·Merel van NulandJos H Beijnen

Related Concepts

Tenormin
Feces
Hydrogen-Ion Concentration
Intravenous Injections
Propanolamines

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Pediculosis pubis

Pediculosis pubis is a disease caused by a parasitic insect known as Pthirus pubis, which infests human pubic hair, as well as other areas with hair including eye lashes. Here is the latest research.

Rh Isoimmunization

Rh isoimmunization is a potentially preventable condition that occasionally is associated with significant perinatal morbidity or mortality. Discover the latest research on Rh Isoimmunization here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells. It also follows CRISPR-Cas9 approaches to generating genetic mutants as a means of understanding the effect of genetics on phenotype.

Enzyme Evolution

This feed focuses on molecular models of enzyme evolution and new approaches (such as adaptive laboratory evolution) to metabolic engineering of microorganisms. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Pharmacology of Proteinopathies

This feed focuses on the pharmacology of proteinopathies - diseases in which proteins abnormally aggregate (i.e. Alzheimer’s, Parkinson’s, etc.). Discover the latest research in this field with this feed.

Alignment-free Sequence Analysis Tools

Alignment-free sequence analyses have been applied to problems ranging from whole-genome phylogeny to the classification of protein families, identification of horizontally transferred genes, and detection of recombined sequences. Here is the latest research.

Related Papers

Xenobiotica; the Fate of Foreign Compounds in Biological Systems
P R ReevesM J Winrow
European Journal of Clinical Pharmacology
J D FitzgeraldJ McAinsh
European Journal of Clinical Pharmacology
J SassardP Zech
European Journal of Drug Metabolism and Pharmacokinetics
W LauwersJ O Bracke
© 2021 Meta ULC. All rights reserved